⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLRB News
Cellectar Biosciences INC NEW
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
globenewswire.com
CLRB
Form 8-K
sec.gov
CLRB
Form 8-K
sec.gov
CLRB
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com
CLRB
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
globenewswire.com
CLRB
Form 8-K
sec.gov
CLRB
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
globenewswire.com
CLRB
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
globenewswire.com
CLRB
Form 8-K
sec.gov
BRNS
MXCT
SLDB
CLRB
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD